Incyte (INCY) - 25 Year Stock Price History

Historical daily stock prices for Incyte since 1993 adjusted for splits and dividends. Open, high, low, close (OHLC) data as well as percentage changes for multiple date ranges. Display 50 and 200 day moving averages and export charts as images to use in articles and blogs. The latest closing price for Incyte (INCY) as of March 22, 2018 is 85.25.

Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $18.056B $1.536B
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. They have a diverse and growing portfolio of product candidates, including both small and large molecules.